Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma

Bai, Menglin; Zou, Benkui; Wang, Zhendan; Pang, Li; Wang, Huansheng; Ou, Yang; Cui, Kai; Bian, Jiasheng; Sheng, Li; Xü, Xinsheng

doi:10.1007/s11255-018-1954-2

Cited by 21 publications

(22 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC is reported to present with lower circulating tumor DNA (ctDNA) levels compared to other tumor entities (Smith et al, 2020), excluding it as a feasible diagnostic marker in RCC. Also, CTCs have not been established for clinical use in RCC diagnosis yet due to heterogenous surface marker expression (Bu et al, 2020), which makes an enrichment with the CellSearch TM system, the only FDA-approved CTC capture platform, difficult (Bai et al, 2018). Therefore, circulating ncRNAs might represent useful and easily available biomarkers in the diagnosis and treatment of RCC.…”

Section: Comparison To Current Standardsmentioning

confidence: 99%

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Barth

Drula

Ott

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Liquid biopsy-the determination of circulating cells, proteins, DNA or RNA from biofluids through a "less invasive" approach-has emerged as a novel approach in all cancer entities. Circulating non-(protein) coding RNAs including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and YRNAs can be passively released by tissue or cell damage or actively secreted as cell-free circulating RNAs, bound to lipoproteins or carried by exosomes. In renal cell carcinoma (RCC), a growing body of evidence suggests circulating non-coding RNAs (ncRNAs) such as miRNAs, lncRNAs, and YRNAs as promising and easily accessible blood-based biomarkers for the early diagnosis of RCC as well as for the prediction of prognosis and treatment response. In addition, circulating ncRNAs could also play a role in RCC pathogenesis and progression. This review gives an overview over the current study landscape of circulating ncRNAs and their involvement in RCC pathogenesis as well as their potential utility as future biomarkers in RCC diagnosis and treatment.

show abstract

Section: Comparison To Current Standardsmentioning

confidence: 99%

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Barth

Drula

Ott

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Our ndings are not identical to previous studies which found that the TNM-Staging are related to the positive rate and level of CTCs. 23,24 One reason could be included that most patients were diagnosised with early clinical TNM Stage.…”

Section: Discussionmentioning

confidence: 99%

“…Compared with the CellSearch system, ISET has a higher detection rate for CTCs of RCC and more advantages in detecting renal cancer CTCs with low expression of EpCAM. 23 In recent studies, markers of G250 antigen 40,41 or CA9 combined with CD147 42 showed good prospects in the detection of CTCs in RCC patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Circulating Tumor Cells and Ki-67 in Renal Cell Carcinoma

Song

Dong

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Renal cell carcinoma (RCC) is a common maligant tumor of the genitourinary system. We aimed to analyze the potential value of the metastasis-related biomarker, circulating tumor cells (CTCs) and proliferative marker Ki-67 in diagnosis of RCC. Methods: Data from 24 laparoscopic radical nephrectomy (RN) and 17 laparoscopic partial nephrectomy (PN) were collected in 2018. The number and positive rate of CTCs and circulating tumor microemboli (CTM) was obtained at three different time points in peripheral blood just before, immediately and one week after surgery. Ki-67 protein expression was evaluated in RCC tissue by immunohistochemistry. Results: No association between the number and positive rate of perioprative CTC and clinicopathological features was found, except for the statistically significant association between the preoprative CTC counts and tumor size. The CTC counts gradually decreased during the perioperative period, and at one week after surgery was significantly lower than that before surgery. Higher Ki-67 expression was signiﬁcantly correlated positively with preoprative CTC counts. In addition, a higher Ki-67 express has been found in high CTCs group (CTCs ≥ 5). Conclusion: Our results suggest that surgical nephrectomy is associated with a decrease in CTC counts of RCC patients. CTCs can act as a potential biomarker for the diagnosis and prognostic of RCC. Careful and sufﬁcient long-term follow-up is needed for patients with high preoprative CTC counts.

show abstract

“…Thanks to various advantages, such as retention of cell morphology, antigen independence, and high sensitivity and specificity, membranous filter devices, for example, isolation by size of epithelial tumor cells (ISET) (Rarecells Diagnostics, Paris, France), have caught more attention in CTC researches. In a comparative study, Bai et al [47] estimated the clinical effect of CTCs by using CellSearch system and ISET devices among patients with renal cell carcinoma (RCC), discovering that ISET was more appropriate for RCC patients. CTCBIOPSY (Wuhan YZY Medical Science and Technology Co., Ltd., China) is a commercial one-step ISET device which could complete automatic detection and identification within 10 min [48] .…”

Section: Size-based Ctc Isolationmentioning

confidence: 99%

Sensitive and specific detection of circulating tumor cells promotes precision medicine for cancer

Huang¹,

Chen²,

Jiang³

et al. 2019

JCMT

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have the potential to provide genetic information for heterogeneous tumors, which may be useful for monitoring disease progression and developing personalized therapies. However, the isolation of CTCs for molecular analysis is challenging due to their extreme rarity and phenotypic heterogeneity, which hinders the transformation of CTCs into traditional clinical applications. In order to achieve clinically significant CTC detection, devices utilizing novel microfluidics and nanotechnology have been developed to achieve high sensitivity and specificity capture of CTCs. In this review, we discuss these newly developed devices for CTC capture and molecular characterization for early diagnosis and determining ideal treatment regimen to better manage these cancers clinically. In addition, the potential prognostic values of CTCs as treatment guidelines and that ultimately contribute to realize personalized treatment are also discussed.

show abstract

Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma

Abstract: We discovered that ISET is more suitable than the CSS for detecting CTCs in RCC patients. The presence of CTCs/CTMs in RCC patients correlated with higher TNM stages, suggesting that the presence of CTCs could be a prognostic marker in RCC patients.

Cited by 21 publications

References 31 publications

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers

Clinical Significance of Circulating Tumor Cells and Ki-67 in Renal Cell Carcinoma

Sensitive and specific detection of circulating tumor cells promotes precision medicine for cancer

Contact Info

Product

Resources

About